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a  b  s  t  r  a  c  t
In epidemiology  studies,  the presence  of  perﬂuorooctanoate  (PFOA)  in human  blood  has
been associated  with  higher  serum  cholesterol  concentrations.  A  possible  explanation  for
these results  is  that  elevated  serum  cholesterol  might  reduce  clearance  of  PFOA.  In  this
study, female  hamsters,  which  transport  and  regulate  cholesterol  in a  manner  similar  to
humans,  were  fed  normal  diet  or diet  supplemented  with  0.05%  cholesterol  and  10%  coconut
oil (high-fat  diet)  resulting  in hyperlipidemia  throughout  the  study  in  supplemented  ani-
mals.  Hamsters  on  either  a normal  and high-fat  diet  were  given  oral  doses  of 0.1,  1.0,  or
10 mg APFO/kg  for 30 days.  Serum  PFOA  concentrations  evaluated  24  h  after  1, 10, 20,  and
30  doses  of  APFO  were  not  altered  in  hyperlipidemic  hamsters  compared  to those  fed nor-
mal diet.  For  a given  dose  group,  serum  concentrations  of  PFOA  were  highest  following
the  10  doses  (except  for  the  10  mg/kg  group  where  concentrations  were  the  highest  after
the ﬁrst  dose)  and were  lowest  after  20 and 30 doses.  Under  the  condition  of  this  study,
higher  serum  lipids did  not  affect  the absorption  and  clearance  of  serum  PFOA.  Serum  PFOA
concentrations  declined  over the  course  of the  study  despite  continued  daily  dosing  with
APFO.  This  does  not support  the hypothesis  that  higher  serum  lipids  might  increase  the
retention  of PFOA  in  the  body.
rs.  Publ
Y-NC-N©  2015  The  Autho
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1. Introduction
Perﬂuorooctanoate (PFOA, CF3(CF2)6COO , CAS No.
335-67-1) is a perﬂuorinated carboxylate ion that has been
used, generally as the ammonium salt (APFO, CAS No. 3825-
26-1), as a surface-active agent in the production of various
ﬂuoropolymers. Because of its chemical stability against
metabolic and environmental degradation and long elim-
ination half-life in humans (approximately 3 years) [1,2],
∗ Corresponding author at: DuPont Sustainable Growth Center, CTLP
708/144, Wilmington, DE 19805, USA. Tel.: +1 3028938161.
E-mail address: gerald.kennedy@dupont.com (G.L. Kennedy).
http://dx.doi.org/10.1016/j.toxrep.2015.01.013
2214-7500/© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open
org/licenses/by-nc-nd/4.0/).ished  by Elsevier  Ireland  Ltd.  This  is  an  open  access  article  under
D  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
PFOA is found widely distributed in the environment [3–9]
and in samples of blood from non-occupationally exposed
populations [10–12]. Recent reports indicate that serum
PFOA concentration in the general population averages less
than 5 ng/mL and appears to have been decreasing since
1999–2000 [11–13].
A positive association of PFOA with serum cholesterol
has been observed in occupational studies [14–18,19],
in an exposed community [20–22], and in one general
population study [23]. These associations between serum
PFOA and cholesterol concentrations varied in statistical
signiﬁcance. Of these studies, all were cross sectional with
the exception of 3 studies with multiple measurements
per subject: Sakr et al. [19] that had multiple PFOA and
 access article under the CC BY-NC-ND license (http://creativecommons.
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holesterol measurements in approximately 450 work-
rs; Costa et al. [14] that had multiple measurements
n 56 workers; and Olsen et al. [17] that had at least 2
easurements for each of 174 workers.
The relationship between cholesterol and PFOA expo-
ure expressed as the change in cholesterol concentration
mg/dL) per change in PFOA concentration (mg/mL) is
ased on the assumption of linearity which is not always
een in the studies reported. The change in cholesterol as
elated to exposure was reviewed by Steenland et al. [22]
nd expressed as a change in cholesterol per mg/mL  change
n serum PFOA. An increase of 1–5 mg/dL cholesterol was
eported in occupationally exposed workers with mean
FOA concentrations of approximately 500–1000 ng/mL
18,19]. An increase of approximately 10 mg/dL choles-
erol was seen in both a PFOA-exposed community [21,24]
ith mean PFOA concentrations of 70–80 ng/mL and in the
eneral population where the mean PFOA concentrations
ere around 4 ng/mL [23]. An increase of 16 mg/dL choles-
erol was reported in an occupationally exposed group
ith mean serum PFOA concentrations of 22,000 ng/mL
25]. Thus the greatest increase in cholesterol concentra-
ion was seen in the general population when the increases
n PFOA concentration were the smallest. In contrast to the
uman epidemiology data, dosing with APFO results in a
ecrease in cholesterol concentration in rodents [26,27]
nd does not impact cholesterol concentrations in monkeys
28].
The lack of a dose-response relationship in human
tudies between the magnitude of cholesterol increases
nd serum PFOA concentrations has not been explained.
he magnitude of cholesterol increases is not consistently
reater in occupationally exposed populations although
his would be the expectation of a cause/effect relationship.
here are 3 possibilities to consider: (1) that PFOA could
irectly increase cholesterol, (2) both PFOA and cholesterol
re increased independently by some other substance or
actor, or (3) high serum lipids might increase retention of
FOA in the body. In rodents, treatment with PFOA has been
hown to decrease cholesterol concentrations rather than
ncrease [29]. No other substance or other factor has been
dentiﬁed to date that increases both cholesterol and PFOA
erum concentrations. Thus, we looked at the last possibil-
ty in an animal model by evaluating uptake and clearance
f PFOA in hamsters given hyperlipidemic diets compared
o hamsters fed normal diets. Hamsters were chosen for
his experiment because they transport and regulate serum
holesterol in a manner that closely resembles humans
30,31]. Hamsters are different from rats and guinea pigs in
hat the rate of hepatic cholesterol synthesis more closely
esembles those typical of humans. Both the hamster and
uman transport a signiﬁcant proportion of plasma choles-
erol in the form of low density lipoproteins (LDL). Similar
echanisms are involved in the regulation of plasma LDL-
holesterol which is responsive to both nutritional and
harmacological manipulation [32]. In addition, hamsters
lso are known to develop hyperlipidemia in response to
igh fat diets [33–35]. In this study, uptake and clearance
f PFOA were evaluated by measuring serum PFOA over a
0 day dosing period in hamsters fed either a normal diet
r a hyperlipidemic diet.gy Reports 2 (2015) 70–77 71
2. Materials and methods
2.1. Test material
The material used in this study was  the linear form of
ammonium perﬂuorooctanoate. This material was  a white
to slightly opaque liquid in a 20.0% solution of APFO in
water. Chemical analysis showed the actual concentration
in the stock solution to be 23.1%. No evidence of instability
such as a change in color or physical state was  observed
under the conditions of this study.
2.2. Animals and husbandry
Forty-six female Golden Syrian hamsters were received
at 47 days of age from the supplier (Harlan, Indianapolis,
IN). Hamsters were housed in stainless-steel, wire-mesh
cages in animal rooms maintained at 22 ± 4 ◦C, a relative
humidity of 50 ± 20%, and a light/dark cycle of 12/12 h. All
hamsters were quarantined for 1 week during which they
were fed normal diet Laboratory Rodent Diet 5001 (meal,
PMI  Nutritional International, St. Louis, MO), observed daily
for clinically apparent signs of disease or injury and were
weighed 3 times. Both water and feed were available ad
libitum. All procedures using animals were reviewed and
approved by Haskell’s Institutional Animal Care and Use
Committee, and the animal program is fully accredited by
the Association for Assessment and Accreditation of Labo-
ratory Animal Care.
2.3. Diet preparation
Coconut oil (Spectrums Essential, Boulder, CO) and
cholesterol (J.T. Baker, Phillipsburg, NJ) were added directly
to PMI  5001 ground chow and thoroughly mixed to attain
homogeneous distribution of the dietary components. The
blended high-fat diet had a ﬁnal concentration of 10%
coconut oil (w/w)  and 0.05% cholesterol (w/w). Diets were
prepared every other week and added to hamster feeder
compartments daily with the remainder refrigerated until
use. All diets were discarded within 2 weeks of preparation.
2.4. Study design
Two weeks prior to dosing, hamsters were assigned
to high-fat and normal diet groups. Mean body weights
between 100 and 120 g in the 2 groups were similar.
Hamsters were maintained on the appropriate diet (either
normal or high-fat) for 14 days prior to ﬁrst administration
of the test material (APFO). Groups of 5 hamsters/diet were
dosed with either 0 (control), 0.1, 1, or 10 mg  APFO/kg for
30 days.
2.5. Dosing methods
Dose solutions were prepared, using the nominal 20%
solution (corrected for actual determined 23.1%), by serial
dilution with Nanopure® water to a ﬁnal concentration of
1 mg  APFO/mL for the 10 mg/kg group. Additional serial
dilutions were used to prepare dose solutions for the 2
lower dosing groups. All dose volumes were 10 mL/kg.
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Samples of dosing solutions were analyzed for APFO con-
centrations near the beginning and end of the study. The
vehicle control was Nanopure® water. Hamsters were
dosed via oral gavage with care being taken not to injure
the animals during treatment.
2.6. Blood collection
Approximately a 0.5 mL  sample of blood was collected
from the orbital sinus of each hamster under carbon diox-
ide anesthesia. The samples were collected 24 h after the
ﬁrst, 10th, 20th, and 30th dose of APFO and prior to the
subsequent dose.
2.7. Analytical
Concentrations of PFOA were measured in hamster
blood serum samples collected in anti-coagulant-free tubes
using a modiﬁed version of the method described in Fla-
herty et al. [36]. Brieﬂy, the stable isotope internal standard
(dual 13C-PFOA-Perkin Elmer, Billerica, MA)  was added to
an aliquot of each sample to facilitate quantiﬁcation. Then
acetonitrile was added and the samples were centrifuged
at 15,000 × g to precipitate protein and extract PFOA. The
samples were then analyzed by reversed-phase liquid chro-
matography with mass spectrometric detection.
A Micromass Quattro Micro tandem mass spectrom-
eter (MS/MS) system (Waters Associates, Milford, MA)
coupled to a Hewlett Packard series 1100 liquid chromato-
graph (Agilent, Little Falls, DE) was used to determine
perﬂuorooctanoate in the dosing solution and in serum.
A 2.1 mm × 150 mm,  5 m Zorbax RX-C8 column (Agilent,
Little Falls, DE) was used at 35 ◦C. Upon injection of 20 L
of sample, a gradient consisting of Mobile Phase A (0.15%
acetic acid on Nanopure® water) and Mobile Phase B (ace-
tonitrile) was initiated at a ﬂow rate of 0.4 mL/min starting
at 5% B and moving to 80% B at 1.0 min. At 6.1 min  the
mobile phase was returned to 5% B until the end of the
run (9 min). The electrospray interface was operated in
the negative ion mode with the 413 → 369 Da transition
monitored for perﬂuorooctanoate and the 415 → 370 Da
transition monitored for the dual 13C internal standard.
The limit of quantitation for PFOA was set at 0.04 ppm and
the limit of detection was 0.01 ppm. Unusually high serum
PFOA concentrations for 2 animals were veriﬁed by repeat
analysis.
2.8. Endpoints
Clinical observations were conducted daily and body
weights were determined weekly on all hamsters. Food
consumption was measured weekly. Serum lipid concen-
trations (triglycerides, cholesterol-total, and HDL) were
measured following 1, 10, 20, and 30 daily doses of
APFO. These lipid parameters were determined using
standard reagents on an Olympus® AU640 (Beckman Coul-
ter) clinical chemistry analyzer (Irving, TX). Serum PFOA
concentrations were analyzed at the same intervals using
the analytical methods described earlier. The primary out-
come tested was the serum PFOA concentration at severalFig. 1. Mean body weights of hamsters fed either a normal or high fat diet
followed by 30-day oral dosing of APFO.
time points as a function of being fed either a high fat con-
tent or a normal rodent diet.
2.9. Scheduled sacriﬁce
After the ﬁnal blood collection (30 days of dosing), ham-
sters were sacriﬁced by carbon dioxide anesthesia and
exsanguinations and discarded. Extra serum was  collected
and saved frozen at −80 ◦C.
2.10. Statistical analysis
Signiﬁcance was judged at p < 0.05. All data was ﬁrst
analyzed by Levene’s test for homogeneity [37] and the
Shapiro–Wilk test [38] for normality. If the preliminary
tests were not signiﬁcant, a one-way analysis of variance
[39] using p-adjusted linear contrasts was performed. If
the preliminary test was signiﬁcant, Dunn’s [40] Type 1
p-adjusted linear contrast test was employed.
3. Results
The dosing solutions contained the proper concentra-
tion of APFO during the experiment. APFO concentrations
were 100.9–107.0%, 103.6–109.0%, and 89.5–111.0% of the
target concentrations for the 0.1, 1.0, and 10 mg/kg dosing
solutions respectively. Analysis of the dosing preparations
determined that the test substance was  at the targeted
levels, was  uniformly mixed (CV’s = 0.6%, 0.0%, and 1%
respectively), and was  stable for 5 h at room temperature
in vehicle. The vehicle dosing solution did not contain any
detectable APFO.
All hamsters survived to scheduled sacriﬁce. No clin-
ical observations were attributed to APFO. Hamsters
in the normal and high-fat diet groups gained body
weight throughout the study. Mean body weight gains
were 36.0/45.7, 39.7/40.2, 40.1/40.0, and 35.1/39.8 g
(normal diet/high-fat diet) for hamsters given 0, 0.1, 1,
and 10 mg/kg, respectively (Fig. 1). Although not statis-
tically signiﬁcant, the 0 and 10 mg/kg animals on the
high-fat diet gained 27% and 13% more weight than did
their counterparts on the normal diets, respectively. The
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Table  1
Serum lipid concentrations in hamsters fed either a normal or high fat diet followed by 30-day oral dosing of APFO.
Diet Group Normal High Fat
APFO dose (mg/kg) 0 0.1 1 10 0 0.1 1 10
Parameter Day
Cholesterol (mg/dL) 1 104 (16) 107 (22) 103 (16) 105 (16) 215 (64) 193 (39) 191 (46) 200 (46)
10  141 (32) 149 (15) 127 (19) 125 (17) 204 (50) 208 (57) 184 (58) 184 (50)
20  120 (25) 133 (8) 117 (24) 97 (18) 152 (13) 167 (29) 156 (49) 159 (23)
30  115 (15) 113 (7) 111 (26) 97 (13) 164 (27) 165 (33) 158 (61) 151 (20)
Triglycerides (mg/dL) 1 204 (67) 199 (76) 166 (22) 189 (44) 343(125) 304 (59) 330 (67) 354 (23)
10  259 (26) 241 (51) 255 (88) 223 (36) 386 (70) 324 (109) 307 (36) 339 (68)
20  217 (38) 242 (52) 233 (57) 209 (42) 316 (33) 273 (77) 330 (57) 271 (68)
30  208 (22) 219 (17) 223 (36) 164 (67) 291 (59) 271 (50) 366 (134) 354 (98)
HDL  (mg/dL) 1 66 (8) 71 (12) 68 (9) 67 (9) 104 (9) 115 (14) 112 (7) 110 (14)
10  90 (17) 102 (9) 86 (15) 86 (12) 136 (23) 132 (20) 119 (21) 122 (21)
95 (2) 
84 (9) 
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dministration of APFO did not affect body weight gains.
amsters sometimes slept in food compartments and food
as occasionally contaminated with feces or urine thus
eabsorption of the chemical was possible.
Serum lipid concentrations including total cholesterol,
DL cholesterol, and triglycerides were higher in ham-
ters fed the high-fat diet than were those fed the normal
iet and were relatively consistent across the time points
valuated (test days 1, 10, 20, 30; Table 1). Mean serum
ipid concentrations in the high-fat diet groups, as a per-
ent of the normal diet group, ranged from 136% to
91%, 128–176%, 138–168%, and 130–234% for triglyc-
ride, total cholesterol, and HDL cholesterol, and non-HDL
espectively. Dosing with APFO did not alter serum lipid
oncentrations in either diet group. For all time points,
erum PFOA concentrations were similar for a given dose
roup in both diets.
Serum PFOA concentrations were generally propor-
ional to administered APFO (Table 2 and Fig. 2). Mean
erum PFOA concentrations were approximately 0.5, 5,
nd 35 g/mL for hamsters given a single dose of 0.1,
, and 10 mg/kg APFO (normal and hyperlipidemic ham-
ters combined), respectively, approximating a linear dose
esponse. After 10 doses, serum PFOA concentrations were
–5 fold higher than after the initial dose in the 0.1 mg/kg
roups and 2-fold higher in the 1 mg/kg groups. Serum
FOA concentrations in these dose groups progressively
ecreased at the next 2 sampling intervals, reaching con-
entrations of approximately 1 and 7–8 g/mL in the 0.1
nd 1 mg/kg groups respectively after 30 days of dosing.
n the 10 mg/kg groups, serum PFOA concentrations pro-
ressively decreased after the ﬁrst time point, and were
pproximately 5–6 g/mL after 30 days of dosing. The
ecrease in serum PFOA concentration was more rapid in
his group compared to the other dose groups.
. DiscussionThe pattern of absorption, distribution, and excretion
f APFO is variable across sexes and species of laboratory
nimals. Both sexes of rabbits and female rats are rapid
xcretors while male rats and both sexes of mice are slow81 (12) 76 (13) 112 (8) 120 (9) 105 (17) 121 (18)
78 (17) 72 (13) 115 (17) 113 (9) 105 (22) 111 (11)
excretors. APFO metabolism has been studied in a single
male and single female hamster following oral administra-
tion using 14C labeled material. The male hamster is a rapid
excretor of PFOA and excretes more than 99% of an APFO
dose within 120 h with negligible tissue retention. In con-
trast, the female hamster excretes PFOA more slowly with
only 60% of an APFO dose excreted within 120 h of dos-
ing. Substantial PFOA residues were present in the blood,
liver, kidneys, lungs and skin at that time point [41]. Blood
was identiﬁed as the tissue storage site for PFOA at 120 h
post-dosing, although PFOA concentrations were not calcu-
lated. In this study, serum PFOA concentrations of female
hamsters were approximately 0.5, 5, and 35 g/mL (0.1, 1.0,
and 10 mg/kg respectively) at 24 h after the ﬁrst oral dose
of APFO. Analyses of serum PFOA concentrations indicate
that our results are similar to those of Hundley et al. [41].
Feeding of diets containing 10% coconut oil and 0.05%
cholesterol did produce a hyperlipidemic state in hamsters.
Serum lipid values were consistent over the duration of the
study for hamsters fed either the normal or high-fat diets.
The individual serum chemistry values for hamsters on the
high-fat diet were above those of any animal fed the normal
diet. Therefore, the high-fat diet was  successful in inducing
a consistently hyperlipidemic state in female hamsters.
Treating hamsters with oral doses of from 0.1 to
10 mg/kg for 30 days did not produce any clinical signs
and body weight data reﬂected no adverse effect. Lipid
measurements, such as triglycerides and cholesterol con-
centrations, showed no change with continuing dosing
with PFOA. These lipid responses are similar to that seen in
the monkey [28] and unlike the decreases seen in rodents
[27].
Serum PFOA concentrations showed signiﬁcant inter-
individual variability as indicated by large standard
deviations of means. Unusually high PFOA serum con-
centrations (veriﬁed by repeat chemical analysis) were
observed in 2 hamsters at 1.0 mg/kg on day 10 (one from
each diet group). A possible explanation for these high
values and the large standard deviations is that hamsters
often were observed inside their food jars, contaminating
food with urine and feces and causing spillage of food.
In addition, hamsters are coprophagic like several other
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Table 2
Serum PFOA concentrations in hamsters fed either a normal or high fat diet followed by 30-day oral dosing of APFO.
Dose (mg/kg/day) Diet Test Day 1 10 20 30
0.0 Normal fat Mean 0.000 0.000 0.000 0.000
SD  0.000 0.000 0.000 0.000
High  fat Mean 0.000 0.000 0.009 0.000
SD  0.000 0.000 0.021 0.000
0.1 Normal fat Mean 0.573 1.898 1.026 0.869
SD  0.0043 0.557 0.357 0.276
High  fat Mean 0.512 2.824 1.820 1.394
SD 0.176 0.906 0.611 0.359
1.0  Normal fat Mean 5.128 9.686 8.630 7.040
SD 0.620 8.435 9.229 9.433
High fat Mean 5.440 10.352 9.028 7.818
SD 0.986 8.852 10.711 11.539
10  Normal fat Mean 34.280 26.242 13.556 5.694
SD 
High fat Mean 
SD 
herbivores [42–44]. This behavior likely resulted in unre-
liable food consumption measurements, as well as the
possibility of re-exposure to PFOA following ingestion of
urine and feces-contaminated food (urine and feces are the
major routes of PFOA elimination in the hamster [41]). In
this experiment, food spillage and hamsters sitting in the
food jars were frequent occurrences with urine and feces
noted in the food jars. When the 2 high serum concentra-
tions at 1.0 mg/kg on day 10 are excluded from the mean,
the day 10 PFOA concentrations for hamsters at 0.1 and
1.0 mg/kg are consistent at days 10, 20, and 30. It is also
possible that the absorption and excretion of APFO/PFOA
is inherently variable in female hamsters. Single animals
were used in the previous study by Hundley et al. [41]
so published data concerning variability in hamster APFO
kinetics is not available.
Feeding of high-fat diet did not alter serum PFOA con-
centrations in hamsters at any dose (0.1, 1.0, and 10 mg/kg).
Fig. 2. Serum PFOA concentrations in hamsters fed either a norm9.964 20.531 11.544 3.652
34.820 20.674 13.410 5.212
15.277 14.001 9.728 1.426
Although mean serum concentrations were usually slightly
higher in hamsters fed a high-fat diet compared to those fed
a normal diet, there was considerable overlap in the PFOA
concentrations of individual animals within a given dose
group and none of the differences were statistically signif-
icant. Therefore, we did not demonstrate any effect of diet
on serum PFOA concentrations in hamsters dosed up to 30
days.
For both dietary groups, the serum PFOA concen-
trations 24 h after the ﬁrst dose were approximately
linear across the APFO dose range (0.1–10 mg/kg). After
subsequent doses at 10 mg/kg, serum concentrations
decreased progressively through day 30. At 0.1 and
1.0 mg/kg mean values were highest following the tenth
dose and decreased progressively following the 20th and
30th dose. Exclusion of 2 outliers at 1.0 mg/kg resulted
in generally consistent PFOA concentrations at days 10,
20, and 30; a similar pattern was observed at 0.1 mg/kg.
al or high fat diet followed by 30-day oral dosing of APFO.
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he reason for decreasing serum PFOA concentrations in
emale hamsters dosed with 10 mg/kg despite continued
aily dosing with APFO was not determined in this study.
he pattern seen here was not seen in rats and monkeys
s in those species an increase, not a decrease, in PFOA
oncentration with continued daily dosing (attaining
 steady state concentration) was reported [28,29,45].
he observation here suggests that either absorption or
xcretion is being altered with repeated doses.
Enzyme induction and metabolism of APFO could result
n lower concentrations with continued dosing, however,
FOA is stable in the blood and to date there is no evidence
f mammalian metabolism of PFOA [46,47]. Distribution
f PFOA to peripheral tissues may  increase after repeated
osing, however, a depot for PFOA has not been detected
n either rodents or the monkey. In rats and mice, PFOA
as been shown to affect expression of renal transporters
ndicating that PFOA may  alter its own excretion [48].
ene array experiments have shown that PFOA decreases
rganic anion transporting polypeptides (Oatp) in the rat
nd mouse liver [49,50]. In male rats, organic anion trans-
orters recycle PFOA from urine back to the blood resulting
n a longer half-life than female rats. Rat renal transporter
at1a1 has been shown to reabsorb PFOA from the urine
48,51,52]. It is possible that PFOA may  induce a renal or bil-
ary/intestinal transporter in hamsters that preferentially
ransports PFOA into urine or feces. In this study, excretion
f PFOA in urine and feces was not determined
An association between serum PFOA concentrations and
ncreased cholesterol levels has been reported in a number
f cross sectional studies and in 3 studies where multiple
easures were obtained (see references in introduction).
 recent longitudinal assessment of lipid parameters in
orkers involved in demolition of perﬂuoroalkyl manu-
acturing facilities failed to show an adverse association
etween serum PFOA and cholesterol, non-HDL choles-
erol, and HDL cholesterol [53]. Several other lines of
vidence argue against causality. First, the lack of an associ-
tion between serum PFOA and cholesterol concentrations
n workers who are more highly exposed [1,14,18,19].
echanistic studies in animals which show that hypo, not
yperlipidemia occurs with increasing exposure to PFOA
5,47]. No changes in cholesterol or perhaps even a decrease
n cholesterol levels in patients in a phase 1 clinical trial
ho have the highest PFOA concentrations ever measured
n humans [54]. Finally, possible biological roles involved
embrane transport, uptake and efﬂux, and dietary factors
ight be involved.
Reverse causality refers to a direction of cause-and-
ffect which is contrary to a common presumption [25].
t could be that the assumption that A causes B may  be
rong and B might cause A. This hamster experiment was
esigned to test the hypothesis that higher lipid levels
ould lead to higher PFOA serum concentrations rather
han the reverse. Other PFOA related associations have
een proposed to occur due to reverse causality. For exam-
le, lower PFOA serum levels have been associated with
igher birth weight (and to a lesser extent length). Physio-
ogical changes during pregnancy causing plasma volume
xpansion can affect pharmacokinetics and can be asso-
iated with birth outcomes. Thus the increased serumgy Reports 2 (2015) 70–77 75
volume normally occurring during pregnancy effectively
dilutes the solute (PFOA). Larger fetuses require larger vol-
umes of serum. This will result in lowered concentrations
of PFOA. Thus it is expected that larger (heavier, longer)
fetuses would be associated with lower PFOA serum lev-
els as a result of normal physiological changes, not that
neonatal weight and length is affected by the PFOA serum
concentration [55,56]. Similarly, longer inter-pregnancy
intervals have been associated with serum PFOA concen-
trations. This is likely also explained by PFOA kinetics
and distribution during pregnancy to the fetus and excre-
tion of PFOA post-pregnancy in breast milk. The longer
the post-pregnancy interval, the more likely it is that the
PFOA concentration will recover to pre-pregnancy con-
centrations. Indeed, ﬁndings in nulligravid women did not
support an association with longer inter-pregnancy inter-
vals [57].
Under the conditions of this study, higher serum lipids
did not affect the toxicokinetics of PFOA in hamsters as
serum PFOA concentrations in hyperlipidemic hamsters
were essentially the same as those fed normal diet. In
this species, serum PFOA concentrations generally declined
over the course of the study despite continued dosing with
APFO at doses between 0.1 and 10 mg/kg. This patterns has
not been seen in other species (rat: [47,58]; mouse: [28];
monkey: [45]) where serum perﬂuorooctanoic acid con-
centrations either rise or reach an apparent steady-state
with repeated doses.
Conﬂict of interest
The authors declare that there are no conﬂicts of inter-
est.
Transparency document
The Transparency document associated with this article
can be found in the online version.
References
[1] G.W. Olsen, J.M. Burris, D.J. Ehresman, J.W. Froehlich, A.M. Seacat,
J.L. Butenhoff, Half-life of serum elimination of perﬂuorooctanesul-
fonate, perﬂuorohexane sulfonate, and perﬂuorooctanoate in retired
ﬂuorochemical production workers, Environ. Health Perspect. 115
(2007) 1298–1305.
[2] S.M. Bartell, A.M. Calafat, C. Lyu, K. Kato, P.B. Ryan, K. Steenland, Rate
of  decline in serum PFOA concentrations after granular activated car-
bon ﬁltration at tow public water systems in Ohio and West Virginia,
Environ. Health Perspect. 118 (2010) 222–228.
[3] J.L. Barber, U. Berger, C. Chaemfa, S. Huber, A. Jahnke, C. Temme, Anal-
ysis of per- and polyﬂuorinated alkyl substances in air samples from
Northwest Europe, J. Environ. Monit. 9 (2007) 530–541.
[4] M.  Houde, J.W. Martin, K.R. Solomon, D.C. Muir, Biological monitor-
ing of polyﬂuoroalkyl substances: a review, Environ. Sci. Technol. 40
(2006) 3463–3473.
[5] C. Lau, K. Anitole, C. Hodes, D. Lai, A. Pfahles-Hutchens, J. Seed, Per-
ﬂuoroalkyl acids: a review of monitoring and toxicological ﬁndings,
Toxicol. Sci. 99 (2007) 366–394.
[6] R. Loos, B.M. Gawlik, G. Locoro, E. Rimaciciute, S. Contini, G. Bidoglio,
EU-wide survey of polar organic persistent pollutants in European
river waters, Environ. Pollut. 157 (2009) 561–568.
[7] B.F. Scott, C. Spencer, S.A. Mabury, D.C. Muir, Poly- and perﬂuorinated
carboxylates in North American precipitation, Environ. Sci. Technol.
40 (2006) 7167–7174.
Toxicolo
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[76 N.E. Everds, G.L. Kennedy / 
[8] G.T. Tomy, W.  Budakowski, T. Halldorson, P.A. Helm, G.A. Stern, K.
Friesen, Fluorinated organic compounds in an eastern Arctic marine
food web, Environ. Sci. Technol. 38 (2004) 6475–6485.
[9] N. Yamashita, K. Kannan, S. Taniyasu, Y. Horii, G. Petrick, T. Garno, A
global survey of perﬂuorinated acids in oceans, Mar. Pollut. Bull. 51
(2005) 658–666.
10] E.A. Emmett, F.S. Shofer, H. Zhang, D. Freeman, C. Desai, L.M. Shaw,
Community exposure to perﬂuorooctanoate: relationships between
serum concentrations and exposure sources, J. Occup. Environ. Med.
48  (2006) 759–770.
11] A.M. Calafat, L.Y. Wong, Z. Kuklenyik, J.A. Reidy, L.L. Needham,
Polyﬂuoroalkyl chemicals in the U.S. population: data from the
National Health and Nutrition Examination Survey (NHANES)
2003–2004 and comparisons to NHANES 1999–2000, Environ.
Health Perspect. 11 (2007) 1596–1602.
12] G.W. Olsen, D.C. Mair, T.R. Church, M.E. Ellefson, W.K. Reagen, T.A.
Boyd, Decline in PFOS and other perﬂuoroalkyl chemicals in Amer-
ican Red Cross adult blood donors, Environ. Sci. Technol. 42 (2008)
4989–4995.
13] H.M. Spliethoff, L. Tao, S.M. Shaver, K.M. Aldous, K.A. Pass, K. Kan-
nan, Use of newborn screening program blood spots for exposure
assessment: declining levels of perﬂuorinated compounds in New
York state infants, Environ. Sci. Technol. 42 (2008) 5361–5367.
14] G. Costa, S. Sartori, D. Consonni, Thirty years of medical surveillance
in perﬂuoroctanoic acid production workers, J. Occup. Environ. Med.
51  (2009) 364–372.
15] G.W. Olsen, J.M. Burris, M.M.  Burlew, J.H. Mandel, Plasma chole-
cystokinin and hepatic enzymes, cholesterol and lipoproteins in
ammonium perﬂuorooctanoate production workers, Drug Chem.
Toxicol. 23 (2000) 603–620.
16] G.W. Olsen, L.R. Zobel, Assessment of lipid, hepatic, and thyroid
parameters with serum perﬂuorooctanoate (PFOA) concentrations in
ﬂuorochemical production workers, Int. Arch. Occup. Environ. Health
81 (2007) 231–246.
17] G.W. Olsen, J.M. Burris, M.M.  Burlew, J.H. Mandel, Epidemi-
ologic assessment of worker serum perﬂuorooctanesulfonate
(PFOS) and perﬂuorooctanoate (PFOA) concentrations and medi-
cal  surveillance examinations, J. Occup. Environ. Med. 45 (2003)
260–270.
18] C.J. Sakr, K.H. Kreckmann, J.W. Green, P.J. Gillies, J.L. Reynolds, R.C.
Leonard, Cross-sectional study of lipids and liver enzymes related to
a serum biomarker of exposure (ammonium perﬂuorooctanoate or
APFO) as part of a general health survey in a cohort of occupationally
exposed workers, J. Occup. Environ. Med. 49 (2007) 1086–1096.
19] C.J. Sakr, R.C. Leonard, K.H. Kreckmann, M.D. Slade, M.R. Cullen, Lon-
gitudinal study of serum lipids and liver enzymes in workers with
occupational exposure to ammonium perﬂuorooctanoate, J. Occup.
Environ. Med. 49 (2007) 872–879.
20] E.A. Emmett, H. Zhang, F.S. Shofer, D. Freeman, C. Desai, L.M. Shaw,
Community exposure to perﬂuorooctanoate: relationships between
serum levels and certain health parameters, J. Occup. Environ. Med.
48 (2006) 771–779.
21] S.J. Frisbee, A.P. Brooks, A. Maher, P. Flensborg, S. Arnold, T. Fletcher,
K. Steenland, A. Shankar, S.S. Knox, C. Pollard, J.A. Halverson, V.M.
Vieira, C. Jin, K.M. Leyden, A. Ducatman, The C8 Health Project:
design, methods, and participants, Environ. Health Perspect. 117
(2009) 1873–1882.
22] K. Steenland, T. Fletcher, D.A. Savitz, Epidemiologic evidence on the
health effects of perﬂuorooctanoic acid (PFOA), Environ. Health Per-
spect. 118 (2010) 1100–1108.
23] J. Nelson, E. Hatch, T. Webster, Exposure to polyﬂuoroalkyl chemicals
and cholesterol, body weight, and insulin resistance in the general
US populations, Environ. Health Perspect. 118 (2010) 197–202.
24] K. Steenland, S. Tinker, S. Frisbee, A. Ducatman, A. Vaccarino, Associ-
ation of perﬂuorooctanoic acid (PFOA) and perﬂuorooctanesulfonate
(PFOS) with serum lipids among adults living near a chemical plant,
Am.  J. Epidemiol. 170 (2009) 1268–1278.
25] G.W. Olsen, J.L. Butenhoff, L.R. Zobel, Perﬂuoroalkyl chemicals and
human fetal development: an epidemiologic review with clinical and
toxicological perspectives, Reprod. Toxicol. 27 (2009) 212–230.
26] G.L. Kennedy, J.L. Butenhoff, G.W. Olsen, J.C. O’Connor, A.M. Seacat,
R.G. Perkins, L.B. Biegel, S.R. Murphy, D.G. Farrar, The toxicology of
perﬂuorooctanoate, Crit. Rev. Toxicol. 34 (2004) 351–384.
27] S.E. Loveless, C. Finlay, N.E. Everds, S.R. Frame, P.J. Gillies, J.C.
O’Connor, C.R. Powley, G.L. Kennedy, Comparative responses of rats
and mice to linear/branched, linear, or branched ammonium perﬂu-
orooctanoate (APFO), Toxicology 220 (2006) 203–217.
28] J.L. Butenhoff, G. Costa, C. Elcombe, D. Farrar, K. Hansen, H. Iwai,
R. Jung, G. Kennedy, P. Lieder, G. Olsen, P. Thomford, Toxicity of
[gy Reports 2 (2015) 70–77
ammonium perﬂuorooctanoate in male cynomolgus monkeys after
oral dosing for 6 months, Toxicol. Sci. 69 (2002) 244–257.
29] R.G. Perkins, J.L. Butenhoff, G.L. Kennedy Jr., M.J. Palazzolo, 13-week
toxicity study of ammonium perﬂuorooctanoate (APFO) in male rats,
Drug Chem. Toxicol. 27 (2004) 361–378.
30] D.K. Spady, J.M. Dietschy, Interaction of dietary cholesterol and
triglycerides in the regulation of hepatic low density lipoprotein
transport in the hamster, J. Clin. Invest. 81 (1988) 300–309.
31] R. Sicart, R. Sable-Amplis, A. Guiro, Comparative studies of the circu-
lating lipoproteins in hamster (Mesocricetus auratus) with a normal or
spontaneous high level of cholesterol in the plasma, Comp. Biochem.
Physiol. 78A (1984) 511–514.
32] S. Goulinet, M.J. Chapman, Plasma lipoproteins in the Golden Syr-
ian  hamster (Mesocricetus auratus): heterogeneity of apo and
apo-1-containing particles, J. Lipid Res. 34 (1993) 943–959.
33] S.J. Robins, J.M. Fasulo, G.M. Patton, E.J. Schaefer, D.E. Smith, J.M.
Ordovas, Gender differences in the development of hyperlipidemia
and atherosclerosis in hybrid hamsters, Metabolism 44 (1995)
1326–1331.
34] S.J. Robins, J.M. Fasulo, C.R. Pritzker, J.M. Ordovas, G.M. Patton, Diur-
nal changes and adaptation by the liver of hamsters to an atherogenic
diet, Am.  J. Physiol. 260 (1995) R1327–R1332.
35] T.A. Wilson, R.J. Nicolosi, C.W. Lawton, J. Babiak, Gender differ-
ences in response to a hypercholesterolemic diet in hamsters: effects
on plasma lipoprotein cholesterol concentrations and early aortic
atherosclerosis, Atherosclerosis 146 (1999) 83–91.
36] J.M. Flaherty, P.C. Connolly, E.R. Decker, S.M. Kennedy, M.E. Ellifson,
W.R. Reagen, B. Szostek, Quantitative determination of perﬂuorooc-
tanoic acid (PFOA) in serum and plasma by liquid chromatography
tandem mass spectrometry, J. Chromatogr. B 819 (2005) 329–338.
37] H. Levene, Robust test for equality of variances, in: J. Olkin (Ed.), Con-
tributions to Probability Statistics, Stanford University Press, Palo
Alto, CA, 1960, pp. 278–298.
38] S.S. Shapiro, M.B. Wilk, An analysis of variance test for normality
(complete samples), Biometrika 52 (1965) 591–601.
39] G.W. Snedecor, W.G. Cochran, Statistical Methods, 6th ed., The Iowa
State University Press, Ames, IA, 1967, pp. 246–248, and 349–352.
40] O.J. Dunn, Multiple comparisons using rank sums, Technometrics 6
(1964) 241–253.
41] S.G. Hundley, A. Sarrif, M.G.L. Kennedy Jr., Absorption, distribution,
and excretion of ammonium perﬂuorooctanoate (APFO) after oral
administration to various species, Drug Chem. Toxicol. 29 (2006)
137–145.
42] K.Y. Ebino, Studies on coprophagy in experimental animals, Exp.
Anim. 42 (1993) 1–9.
43] H. Hirakawa, Coprophagy in leporids and other mammalian herbi-
vores, Mammal Rev 31 (2001) 61–80.
44] T. Takahashi, E. Sakaguchi, Behaviors and nutritional importance of
coprophagy in captive adult and young nutrias (Myocastor coypus), J.
Comp. Physiol. B 168 (1998) 281–288.
45] J.L. Butenhoff, G.L. Kennedy Jr., P.M. Hinderliter, P.H. Lieder, R. Jung,
K.J. Hansen, G.S. Gorman, P.E. Noker, P.J. Thomford, Pharmacokine-
tics of perﬂuorooctanoate in Cynomolgus monkeys, Toxicol. Sci. 82
(2004) 394–406.
46] R.A. Kemper, D.L. Nabb, In vitro studies in microsomes from rat and
human liver, kidney, and intestine suggest that perﬂuorooctanoic
acid is not a substrate for microsomal UDP-glucuronyltransferases,
Drug Chem. Toxicol. 28 (2005) 281–287.
47] G.L. Kennedy Jr., G.T. Hall, M.R. Brittelli, J.R. Barnes, H.C. Chen, Inhala-
tion toxicity of ammonium perﬂuorooctanoate, Food Chem. Toxicol.
24  (1986) 1325–1329.
48] X. Han, D.L. Nabb, M.H. Russell, G.L. Kennedy, R.W. Rickard, Renal
elimination of perﬂuorocarboxylates (PFCAs), Chem. Res. Toxicol. 25
(2012) 35–46.
49] K.S. Guruge, L.W. Yeung, N. Yamanaka, S. Miyazaki, S. Lam, P.K. Giesy,
P.D. Jones, N. Yamashita, Gene expression proﬁles in rat liver treated
with perﬂuorooctanoic acid (PFOA), Toxicol. Sci. 89 (2006) 93–107.
50] X. Cheng, C.D. Klaassen, Critical role of PPAR in
perﬂuorooctanoic-acid and perﬂuorodecanoic acid-induced
down regulation of Oatp uptake transporters in mouse livers,
Toxicol. Sci. 106 (2008) 37–45.
51] C.-H. Yang, K.P. Glover, X. Han, Organic anion transporting polypep-
tide  (Oatp)1a1 mediated perﬂuorooctanoate transport and evidence
for  a renal reabsorption mechanism of Oatp1a1 in renal elimination
of perﬂuorocarboxylates in rats, Toxicol. Lett. 190 (2009) 163–171.
52] Y.M. Weaver, D.J. Ehresman, J.L. Butenhoff, B. Hagenbuch, Roles of
rat  renal organic anion transporters in transporting perﬂuorinated
carboxylates with different chain lengths, Toxicol. Sci. 113 (2010)
305–313.
Toxicolo
[
[
[
[
[N.E. Everds, G.L. Kennedy / 
53] G.W. Olsen, D.J. Ehresman, B.D. Buehrer, B.A. Gibson, J.L. Buten-
hoff, L.R. Zobel, Longitudinal assessment of lipid and hepatic
clinical parameters in workers involved with the demolition
of perﬂuoroalkyl manufacturing facilities, JOEM 54 (2012)
974–983.
54] I.R. Macpherson, D. Bissett, R.D. Petty, L.M. Tait, S.J. MacDonald, M.
Smith, A.L. Birse-Archbold, C.R. Barnett, C.R. Wolf, C.R. Elcombe, A.
Jeynes-Ellis, T.R.J. Evans, A ﬁrst-in-human phase 1 clinical trial of
CXR 1002 in patients with advanced cancer, J. Clin. Oncol. 29 (Suppl.)
(2011).
55] K.W. Whitworth, L.S. Haug, D.D. Baird, G. Becher, J.A. Hoppin,
R.  Skjaerven, C. Thomsen, M.  Eggesbo, G. Travlos, R. Wilson,
L.A. Cupul-Ulcab, A.L. Brantsaeter, M.P. Longnecker, Perﬂuorinated
[gy Reports 2 (2015) 70–77 77
compounds in relation to birth weight in the Norwegian Mother and
Child Cohort Study, Am. J. Epidemiology 175 (2012) 1209–1216.
56] A.E. Loccisano, J.L. Campbell Jr., J.L. Butenhoff, M.E. Andersen, H.J.
Clewell 3rd, Comparison and evaluation of pharmacokinetics of PFOA
and PFOS in the adult rat using a physiologically based pharmacoki-
netic model, Reprod. Toxicol. 33 (2011) 452–467.
57] K.W. Whitworth, L.S. Haug, D.D. Baird, G. Becher, J.A. Hoppin, R.
Skjaerven, C. Thomsen, M.  Eggesbo, G. Travlos, R. Wilson, M.P. Long-
necker, Perﬂuorinated compounds and subfecundity in pregnant
women, Epidemiology 23 (2011) 1–7.
58] H. Hanhijarvi, M.  Ylinin, A. Kojo, V. Kosma, Elimination and toxicity
of perﬂuorooctanoic acid during subchronic administration to the
Wistar rat, Pharmacol. Toxicol. 61 (1987) 66–68.
